ECSP20023795A - Compuesto de pirimidina como inhibidor de las janocinasas - Google Patents
Compuesto de pirimidina como inhibidor de las janocinasasInfo
- Publication number
- ECSP20023795A ECSP20023795A ECSENADI202023795A ECDI202023795A ECSP20023795A EC SP20023795 A ECSP20023795 A EC SP20023795A EC SENADI202023795 A ECSENADI202023795 A EC SENADI202023795A EC DI202023795 A ECDI202023795 A EC DI202023795A EC SP20023795 A ECSP20023795 A EC SP20023795A
- Authority
- EC
- Ecuador
- Prior art keywords
- compound
- inhibitor
- janocinases
- pyrimidine compound
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Dental Preparations (AREA)
Abstract
La invención proporciona un compuesto de la fórmula (I): o una sal farmacéuticamente aceptable de este, que es un inhibidor de las janocinasas (JAK). La invención también proporciona composiciones farmacéuticas que comprenden dicho compuesto, una forma cristalina, métodos de uso de dicho compuesto para tratar enfermedades inflamatorias de la piel y otras enfermedades, y procesos y productos intermedios útiles para preparar dicho compuesto.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762577852P | 2017-10-27 | 2017-10-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP20023795A true ECSP20023795A (es) | 2020-06-30 |
Family
ID=64277858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202023795A ECSP20023795A (es) | 2017-10-27 | 2020-04-27 | Compuesto de pirimidina como inhibidor de las janocinasas |
Country Status (38)
| Country | Link |
|---|---|
| US (7) | US10308646B2 (es) |
| EP (1) | EP3672965B1 (es) |
| JP (1) | JP7218364B2 (es) |
| KR (1) | KR102613503B1 (es) |
| CN (1) | CN111247142B (es) |
| AR (1) | AR113803A1 (es) |
| AU (1) | AU2018354370B2 (es) |
| BR (1) | BR112020008015A2 (es) |
| CA (1) | CA3074034A1 (es) |
| CL (1) | CL2020001090A1 (es) |
| CR (1) | CR20200180A (es) |
| CU (1) | CU24671B1 (es) |
| DK (1) | DK3672965T3 (es) |
| DO (1) | DOP2020000083A (es) |
| EA (1) | EA202091016A1 (es) |
| EC (1) | ECSP20023795A (es) |
| ES (1) | ES2932526T3 (es) |
| GE (2) | GEAP202115340A (es) |
| HR (1) | HRP20221221T1 (es) |
| HU (1) | HUE060401T2 (es) |
| IL (1) | IL274037B2 (es) |
| LT (1) | LT3672965T (es) |
| MA (1) | MA49956B1 (es) |
| MD (1) | MD3672965T2 (es) |
| MX (1) | MX2020004255A (es) |
| NI (1) | NI202000032A (es) |
| PE (1) | PE20201495A1 (es) |
| PH (1) | PH12020500528A1 (es) |
| PL (1) | PL3672965T3 (es) |
| PT (1) | PT3672965T (es) |
| RS (1) | RS63608B1 (es) |
| SG (1) | SG11202001706RA (es) |
| SI (1) | SI3672965T1 (es) |
| SM (1) | SMT202200409T1 (es) |
| TW (1) | TWI789446B (es) |
| UA (1) | UA125130C2 (es) |
| WO (1) | WO2019084383A1 (es) |
| ZA (1) | ZA202001641B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA49956B1 (fr) * | 2017-10-27 | 2022-11-30 | Theravance Biopharma R&D Ip Llc | Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak |
| CN115925705B (zh) * | 2018-11-30 | 2024-12-31 | 江苏豪森药业集团有限公司 | 杂芳类衍生物调节剂、其制备方法和应用 |
| JP7470713B2 (ja) * | 2019-04-24 | 2024-04-18 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | Ｊａｋキナーゼ阻害剤としてのエステルおよびカルボナートピリミジン化合物 |
| JP7482152B2 (ja) * | 2019-04-24 | 2024-05-13 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | 皮膚疾患の処置のためのピリミジンｊａｋ阻害剤 発明の背景 |
| BR112023001283A2 (pt) * | 2020-07-28 | 2023-02-14 | Arcutis Biotherapeutics Inc | Composição farmacêutica tópica; método para tratar uma doença, distúrbio ou afecção inflamatória de pele em um indivíduo que necessita do mesmo; e método para intensificar a penetração em pele em um indivíduo de uma formulação farmacêutica tópica |
| JP2023543670A (ja) * | 2020-08-26 | 2023-10-18 | ナロ・セラピューティクス | Ｍｙｃファミリー癌原遺伝子タンパク質のモジュレーター |
| WO2022076771A1 (en) * | 2020-10-08 | 2022-04-14 | Icahn School Of Medicine At Mount Sinai | Compositions for treatment alopecia areata, biomarkers for treatment success, and methods of use thereof |
| JP2024516299A (ja) * | 2021-05-03 | 2024-04-12 | インサイト・コーポレイション | 結節性痒疹の治療のためのルキソリチニブ |
| TW202311256A (zh) * | 2021-06-18 | 2023-03-16 | 美商基利科學股份有限公司 | 用於治療ｆｘｒ誘發之搔癢之ｉｌ－３１調節劑 |
| KR20240111312A (ko) | 2021-10-25 | 2024-07-16 | 카이메라 쎄라퓨틱스 인코포레이티드 | Tyk2 분해제 및 이의 용도 |
| EP4447930A1 (en) | 2021-12-15 | 2024-10-23 | Arcutis Biotherapeutics, Inc. | Stable formulations of shr0302 |
| CN114246938A (zh) * | 2022-01-25 | 2022-03-29 | 中山大学中山眼科中心 | Il-4在制备用于治疗视网膜变性疾病药物中的应用 |
| CN115487301B (zh) * | 2022-11-08 | 2023-07-07 | 四川大学华西医院 | Il-13抑制剂在制备延缓或治疗视网膜色素变性的药物中的用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4919934A (en) | 1989-03-02 | 1990-04-24 | Richardson-Vicks Inc. | Cosmetic sticks |
| US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| AU2001290912A1 (en) | 2000-09-15 | 2002-03-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| BR0116493A (pt) | 2000-12-21 | 2003-09-30 | Vertex Pharma | Compostos de pirazol úteis como inibidores de proteìna cinase |
| JP2008525422A (ja) | 2004-12-23 | 2008-07-17 | ファイザー・プロダクツ・インク | 抗癌剤として有用な複素芳香族誘導体 |
| ATE508126T1 (de) | 2005-11-16 | 2011-05-15 | Vertex Pharma | Als kinaseinhibitoren geeignete aminopyrimidine |
| TW200817391A (en) | 2006-06-30 | 2008-04-16 | Astrazeneca Ab | Novel compounds |
| AU2007269540B2 (en) | 2006-07-05 | 2013-06-27 | Exelixis, Inc. | Methods of using IGF1R and Abl kinase modulators |
| RU2014129740A (ru) | 2011-12-22 | 2016-02-10 | Ф.Хоффманн-Ля Рош Аг | Производные 2,4-диаминопиримидина в качестве ингибиторов серин/треонин киназы |
| WO2015094803A1 (en) | 2013-12-16 | 2015-06-25 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| NO2721710T3 (es) | 2014-08-21 | 2018-03-31 | ||
| JP2017535520A (ja) * | 2014-09-30 | 2017-11-30 | ハンミ・ファイン・ケミカル・カンパニー・リミテッドＨａｎｍｉ Ｆｉｎｅ Ｃｈｅｍｉｃａｌ Ｃｏ．， Ｌｔｄ． | 高純度の（ｒ）−９−［２−（ホスホノメトキシ）プロピル］アデニンの製造方法 |
| ES2924698T3 (es) | 2015-05-28 | 2022-10-10 | Theravance Biopharma R&D Ip Llc | Proceso e intermedios para la preparación de compuestos de naftiridina como inhibidores de quinasa JAK |
| EP3347097B1 (en) | 2015-09-11 | 2021-02-24 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora |
| WO2017189822A1 (en) | 2016-04-28 | 2017-11-02 | Theravance Biopharma R&D Ip, Llc | Pyrimidine compounds as jak kinase inhibitors |
| MA49956B1 (fr) | 2017-10-27 | 2022-11-30 | Theravance Biopharma R&D Ip Llc | Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak |
| JP7482152B2 (ja) | 2019-04-24 | 2024-05-13 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | 皮膚疾患の処置のためのピリミジンｊａｋ阻害剤 発明の背景 |
| JP7470713B2 (ja) | 2019-04-24 | 2024-04-18 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | Ｊａｋキナーゼ阻害剤としてのエステルおよびカルボナートピリミジン化合物 |
-
2018
- 2018-10-26 MA MA49956A patent/MA49956B1/fr unknown
- 2018-10-26 US US16/171,693 patent/US10308646B2/en active Active
- 2018-10-26 IL IL274037A patent/IL274037B2/en unknown
- 2018-10-26 WO PCT/US2018/057682 patent/WO2019084383A1/en not_active Ceased
- 2018-10-26 SM SM20220409T patent/SMT202200409T1/it unknown
- 2018-10-26 SI SI201830770T patent/SI3672965T1/sl unknown
- 2018-10-26 KR KR1020207012597A patent/KR102613503B1/ko active Active
- 2018-10-26 BR BR112020008015-2A patent/BR112020008015A2/pt active Search and Examination
- 2018-10-26 AR ARP180103131A patent/AR113803A1/es unknown
- 2018-10-26 PT PT188011712T patent/PT3672965T/pt unknown
- 2018-10-26 PE PE2020000414A patent/PE20201495A1/es unknown
- 2018-10-26 PL PL18801171.2T patent/PL3672965T3/pl unknown
- 2018-10-26 HU HUE18801171A patent/HUE060401T2/hu unknown
- 2018-10-26 RS RS20220903A patent/RS63608B1/sr unknown
- 2018-10-26 MD MDE20200681T patent/MD3672965T2/ro not_active IP Right Cessation
- 2018-10-26 LT LTEPPCT/US2018/057682T patent/LT3672965T/lt unknown
- 2018-10-26 EP EP18801171.2A patent/EP3672965B1/en active Active
- 2018-10-26 GE GEAP202115340A patent/GEAP202115340A/en unknown
- 2018-10-26 ES ES18801171T patent/ES2932526T3/es active Active
- 2018-10-26 CA CA3074034A patent/CA3074034A1/en active Pending
- 2018-10-26 MX MX2020004255A patent/MX2020004255A/es unknown
- 2018-10-26 SG SG11202001706RA patent/SG11202001706RA/en unknown
- 2018-10-26 EA EA202091016A patent/EA202091016A1/ru unknown
- 2018-10-26 CR CR20200180A patent/CR20200180A/es unknown
- 2018-10-26 DK DK18801171.2T patent/DK3672965T3/da active
- 2018-10-26 GE GEAP201815340A patent/GEP20227344B/en unknown
- 2018-10-26 CU CU2020000053A patent/CU24671B1/es unknown
- 2018-10-26 UA UAA202003146A patent/UA125130C2/uk unknown
- 2018-10-26 AU AU2018354370A patent/AU2018354370B2/en active Active
- 2018-10-26 JP JP2020523324A patent/JP7218364B2/ja active Active
- 2018-10-26 CN CN201880068081.5A patent/CN111247142B/zh active Active
- 2018-10-26 TW TW107137865A patent/TWI789446B/zh active
- 2018-10-26 HR HRP20221221TT patent/HRP20221221T1/hr unknown
-
2019
- 2019-04-22 US US16/390,175 patent/US10562894B2/en active Active
-
2020
- 2020-01-08 US US16/737,067 patent/US10774080B2/en active Active
- 2020-03-13 PH PH12020500528A patent/PH12020500528A1/en unknown
- 2020-03-16 ZA ZA2020/01641A patent/ZA202001641B/en unknown
- 2020-04-23 CL CL2020001090A patent/CL2020001090A1/es unknown
- 2020-04-24 NI NI202000032A patent/NI202000032A/es unknown
- 2020-04-27 EC ECSENADI202023795A patent/ECSP20023795A/es unknown
- 2020-05-06 DO DO2020000083A patent/DOP2020000083A/es unknown
- 2020-08-12 US US16/991,268 patent/US10988470B2/en active Active
-
2021
- 2021-03-30 US US17/301,243 patent/US11420965B2/en active Active
-
2022
- 2022-06-30 US US17/855,539 patent/US11814377B2/en active Active
-
2023
- 2023-10-03 US US18/480,442 patent/US12172994B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2020000083A (es) | Compuesto de pirimidina como inhibidor de las janocinasas | |
| CO2019011809A2 (es) | Compuestos de imidazo-piperidina fusionada como inhibidores de jak | |
| CO2018005640A2 (es) | Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria | |
| CO2018011408A2 (es) | Compuestos de pirimidina como inhibidores de la quinasa jak | |
| CO2017012267A2 (es) | Compuestos de naftiridina como inhibidores de la quinasa jak | |
| CO2021002977A2 (es) | Dimetilaminoazetidinaminas como inhibidores de jak | |
| BR112021007788A8 (pt) | Composto inibidor de jak 2-azabiciclo hexano | |
| CO2020001469A2 (es) | Compuestos bicíclicos de pirazol y triazolo como inhibidores de las cinasas jak | |
| MX2018015625A (es) | Compuestos y composiciones para inhibir la actividad de shp2. | |
| EA201791576A1 (ru) | Ингибитор jak | |
| CR20130560A (es) | Compuestos de bezotiazol y su uso farmacéutico | |
| CO6660497A2 (es) | Derivados del ácido nft-2-ilacético para tratar el sida | |
| PH12021550388A1 (en) | Process for preparing jak inhibitors and intermediates thereof | |
| MX2019014054A (es) | Profarmacos de glucuronida de inhibidores de la cinasa janus. | |
| CO2021002976A2 (es) | Amidas heterocíclicas de 5 a 7 miembros como inhibidores de jak | |
| MX2020004283A (es) | Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6. | |
| CO2020000371A2 (es) | Intermedios útiles para la síntesis de un inhibidor selectivo contra proteín cinasas y procesos para preparar los mismos | |
| UY39181A (es) | COMPUESTOS Y COMPOSICIONES PARA INHIBIR LA ACTIVIDAD DE HIF2a Y SUS MÉTODOS DE USO | |
| CO2019001644A2 (es) | Derivado de triazolopirazinona útil como un inhibidor de pde1 humana | |
| AR102569A1 (es) | Síntesis de inhibidor de pi3k, formas cristalinas y sales del mismo y una composición farmacéutica que lo comprende |